Bino Pathiparampil

Had this ban not come through, Ranbaxy would have launched Diovan and Nexium generic from Toansa facility - that is procured API from Toansa unit and formulated in Ohm Laboratories in the US. But now if it has to depend on a third party for API, then product launches can get delayed by 6-12 months.

Analysts advise how to trade Ranbaxy, say EBITDA may fall

Toansa is the fourth unit of the company which is banned and added to consent decree. With this, all of the company's India-based plants supplying to US are banned. Its Ohm Laboratories, the only plant which has USFDA approval, manufactures drugs using API from Toansa.

IIFL's best bet from 'promising pharma' space

Bino Pathiparampil, vice president research, Institutional Equities picks Sun Pharma as his top pick in the sector, but is cautious on Lupin as he sees some headwinds for the stock over the next two years.

Dr Reddy's Lab top pick in pharma: IIFL Capital

Bino Pathiparampil of IIFL Capital told CNBC-TV18 that there has been a major rally in the sector over the last couple of years. Thus, many of the stocks went up 20 percent in the last couple of months itself.

Expect 20% return in Sun Pharma: IIFL

Expect 20% return in Sun Pharma, says Bino Pathiparampil, IIFL Institutional Equities.

Cash flow improvement may lead to Glenmark re-rating: IIFL

Cash flow improvement may lead to Glenmark re-rating, says Bino Pathiparampil, IIFL Institutional Equities.

See 20% annual returns from Sun Pharma: IIFL Instl Eq

According to pharma analyst Bino Pathiparampil of IIFL Institutional Equities Sun Pharma could make USD 100 million from Doxil.

Buy Dr Reddy's; Divis Lab, Biocon good bets: IIFL Cap

Concentrating on the pharma space, Bino Pathiparampil of IIFL Capital told CNBC-TV18 the success of Biocon‘s oral insulin product deal would be a positive for the company. He also has a buy on Dr Reddy‘s and believes it should give a 25 percent plus upside in the next one year.

See good upside in Dr Reddy's, Divis, Torrent Pharma: IIFL

Bino Pathiparampil of IIFL is bullish on Dr. Reddy‘s, Divi‘s Laboratories and Torrent Pharma. These stocks have attractive valuations and strong growth prospects. "These three stocks have good upside even in this market," he told CNBC-TV18.

Earnings watch: Which pharma co is in pink of its health?

In an interview to CNBC-TV18 Bino Pathiparampil of IIFL shared his expectation from various pharmaceutical companies ahead for their earnings.

IIFL expects good earnings in pharma; picks Glenmark, Cipla

Although the rupee depreciation has been a cause of concern for the economy, pharma companies are going to benefit from it and post good earnings this quarter, believes Bino Pathiparampil, Vice President Research, Institutional Equities, IIFL.

Budget Reactions: IIFL Cap neutral on Cadilla; little downside on Sun Pharma

In an interview to CNBC-TV18, Bino Pathiparampil, vice president, IIFL Capital analyses the pharma sector wherein he reviews specific stocks like Sun Pharma and Cadila.

IIFL on pharma stocks: Ranbaxy, Cipla, Lupin, Sun Pharma

Bino Pathiparampil of IIFL takes CNBC-TV18’s investors through the pharma sector where he looks at select stocks like Ranbaxy, Sun Pharma, Cipla, Lupin, and Wockhardt.

Pharma pack: IIFL Cap likes Dr Reddy's, Cadila, Sun Pharma

Pharmaceutical stocks have been one of the strongest performers over the last few days. In an interview with CNBC-TV18, Bino Pathiparampil, vice president, IIFL Capital said, he is positive on Dr Reddy’s, Cadila and Sun Pharma.

Dr Reddys Laboratories looks cheap: IIFL Capital

Dr Reddys Laboratories is looking cheap, says Bino Pathiparampil, Vice President of IIFL Capital.

IIFL Capital view on Glenmark Pharma

Glenmark’s domestic business is doing pretty well, growing reasonably well, good margins and cash generating business, says Bino Pathiparampil, Vice President of IIFL Capital.

Ranbaxy looks expensive: IIFL Capital

Ranbaxy Laboratories is looking expensive at these levels, says Bino Pathiparampil, Vice President of IIFL Capital.

IIFL's prescription on how to play the pharma space

In an interview with CNBC-TV18, Bino Pathiparampil, vice president of IIFL Capital, spoke about the latest happenings in the pharma space and his call various stocks.